Introduction
============

Down\'s syndrome screening is offered to all pregnant women in many counties ([@b1-etm-0-0-4272]). Conventionally, the combined screening test involving fetal ultrasound examination and maternal serum biomarkers determination ([@b2-etm-0-0-4272]) is used to generate a risk assessment. Generally, such a procedure is performed at a gestational age of 10 weeks and 14+1 weeks with a rate of detection \~85% with a rate of false positive of 2.5% ([@b3-etm-0-0-4272]).

To the best of our knowledge, the majority of pregnant women wanted to be informed if Down\'s syndrome was suspected. On clinical suspicion, most of them would prefer to undergo an invasive diagnostic procedure, which is currently the main method in clinical practice. Accordingly, invasive tests may carry a risk of miscarriage of \~0.5% ([@b4-etm-0-0-4272]). Extensive studies have been focused on developing an alternative method with highflyer or equal accuracy and non-invasive features ([@b5-etm-0-0-4272],[@b6-etm-0-0-4272]). Non-invasive prenatal testing (NIPT) for fetal aneuploidies is now available and is generally suggested as a screening test in clinical practice ([@b7-etm-0-0-4272]). Up to now, NIPT has been considered as committee opinions or guidelines for the clinical screening for the more common autosomal trisomies, such as trisomy 13 (T13), T18 and T21 ([@b8-etm-0-0-4272],[@b9-etm-0-0-4272]). However, only few studies have reported the use of NIPT for the prenatal screening of Down\'s syndrome due to small sample size.

In the present study, we report a performance evaluation of NIPT-based Down\'s syndrome screening in our hospital with a large patient cohort of 1,901 singleton pregnancies. Our study indicated that NIPT is feasible for the prenatal screening of T18 and T21 with higher sensitivity and specificity for the Down\'s syndrome screening, compared with conventional methods.

Patients and methods
====================

### Patients

The study protocols were approved by the Ethics Committee of Maternal and Children\'s Hospital of Shaanxi Province (Xi\'an, China). Written informed consent was obtained from each patient. The study was a retrospective analysis of NIPT in singleton pregnancy over the period from March 2012 to March 2015 at the Maternal and Children\'s Hospital of Shaanxi Province. The prenatal screening test findings for common fetal aneuploidies, including T13, T18 and T21, were set as previously described ([@b10-etm-0-0-4272]). The NIPT test is offered routinely as a prenatal screening test for common fetal aneuploidies, including T13, T18 and T21 to pregnant women with risk factors of one or more anomaly. In total, 1,901 pregnant women (19--45 years, median 30.57 years) received the NIPT test, and all received prior prenatal screening (Down\'s syndrome screening).

### Sequencing

Maternal peripheral blood (5 ml) was collected in an ethylenediaminetetraacetic acid (EDTA) tube at a gestational age of 12+0 to 35+6 weeks. The blood sample was stored at 4°C immediately after collection. Plasma was isolated within 8 h with a two-step centrifugation protocol according to the previous description ([@b11-etm-0-0-4272]). Subsequently, samples were delivered at −80°C to the ISO/IEC 17025 (International Organization for Standardization/International Electro technical Commission)-certified at Shenzhen BGI Clinical Laboratory Center (Shenzhen, China). The cell-free DNA extraction, library construction, sequencing, and bioinformatics analysis were performed according to the previous study ([@b11-etm-0-0-4272]).

### Bioinformatics analysis

Sequencing data were analyzed using a proprietary algorithm. The binary hypothesis T-score of particular chromosomes in each sample was determined, as reported previously ([@b11-etm-0-0-4272]). Briefly, to assess the fetal risk of T21, T18 and T13, the sample with a T-score ≥3.0 for these chromosomes was classified as positive, whereas a T-score \<3.0 was classified as negative for the indicated trisomy.

### Karyotype analysis and amniotic fluid puncture

Women with positive NIPT results were recommended to receive karyotype analysis and amniotic fluid puncture for further validation. The amniotic fluid puncture was performed as routinely described. The karyotype analysis was performed according to the International System for Human Cytogenetic Nomenclature guidelines ([@b12-etm-0-0-4272]).

### Follow-up

Follow-up was performed to NIPT negativity cases via telecommunication. The follow-up duration was 56 days after delivery. A total of 396 cases were lost to follow-up.

Results
=======

### Patient characteristics

A total of 1,901 pregnant women of Han Chinese background, with a mean maternal age of 30.57 years (19--45 years), were included in this study. The gestational age was from 12 weeks to 32+6 weeks at blood sample collection. The patient characteristics were listed in [Table I](#tI-etm-0-0-4272){ref-type="table"}. All these patients received prior screening tests using conventional methods previously, and most of them were classified as risks for T21 and/or T18. However, among these patients, 22 cases were classified by the NIPT to be positive for the T21 (n=15), T18 (n=5) and T13 (n=2), respectively. While the others (n=1,879) were classified to be NIPT negative cases.

### Karyotype confirmation

Among the 22 pregnant women confirmed with positivity of NIPT tests, 15 showed high risks for T21, 5 showed high risks for T18 and 2 showed high risks for T13, respectively ([Table II](#tII-etm-0-0-4272){ref-type="table"}). Finally, 16 underwent amniotic fluid puncture for further validation. Among the 15 cases with high risks of T21, the karyotype results were confirmed with T21 in 12 cases, while the other 3 refused the amniotic fluid puncture. Three underwent amniotic fluid puncture among the 5 cases with high risk of T18. Karyotype results indicated normal karyotype in 2 patients, while the other one showed karyotype of 47, XY,+18 (70%) and 48, XYY,+18 (30%). Among the 2 cases with high risks of T13, 1 declined to receive the amniotic fluid puncture, while the other 1 showed a normal karyotype.

### Pregnancy outcome

The fetal outcome data for the 6 pregnant women with NIPT-positivity but declined to undergo amniotic fluid puncture were obtained after the expected confinement date. All the 12 pregnant women validated with T21 through karyotype decided termination of pregnancy. For the 3 pregnant women with NIPT-positivity declining to receive amniotic fluid puncture, the fetal outcome in 2 cases were intrauterine fetal death while the other 1 was lost in the follow-up. One pregnant with NIPT positivity with high risks for T18 still decided delivery without undergoing amniotic fluid puncture. Another two pregnant women with NIPT positivity with high risks for T13 and T18 decided to determine the pregnancy. One pregnant woman decided to terminate the pregnancy after classified as NIPT positivity after karyotype analysis ([Table II](#tII-etm-0-0-4272){ref-type="table"}).

In the 1,879 cases with negative NIPT testing, the fetal outcome data were obtained in 1,483 cases, while 396 were in lost. The majority of cases (75.47%) were normal at birth. Neonatal death was observed in 1 case. Five pregnant women decided termination of pregnancy despite the presence of NIPT negativity ([Table III](#tIII-etm-0-0-4272){ref-type="table"}).

### Evaluation of NIPT capacity

Among the 1,879 cases with NIPT negativity, follow-up was successfully performed in 1,504 cases including 21 with NIPT positivity and 1,483 with NIPT negativity. The stillbirth cases (n=60) were excluded from the NIPT performance evaluation. Thus, a total of 1,444 cases were used for the analysis finally. The sensitivity of the prior screening test for T21 was 88.89%, but the specificity was only 29.13% ([Table IV](#tIV-etm-0-0-4272){ref-type="table"}). Among the 15 cases classified as NIPT positivity for T21, one patient was lost in the follow-up. Thus, 14 patients were included in the analysis, and the sensitivity and specificity were both at 100%. For the conventional screening test, the respective sensitivity and specificity for the T18, were 73.27 and 98.20% while the sensitivity and specificity for the NIPT were 100 and 99.86%, respectively ([Table IV](#tIV-etm-0-0-4272){ref-type="table"}).

Discussion
==========

NIPT has been widely used for the prenatal screening of T21, T18 and T13 in the last few years. Up to now, it is still lacking large scale clinical studies focused on the efficiency in the general population. Besides, there are really some concerns on the clinical performance. The present study including 1,901 cases was performed to investigate the clinical performance of NIPT on the sensitivity and specificity on the screening of T21, T18 and T13, respectively.

Conventional prenatal screening involves amniotic fluid puncture, chorionic villus sampling and umbilical vein puncture ([@b13-etm-0-0-4272]). However, these methods are invasive and cause high risks of infection, and even abortion. Recently, NIPT for common fetal aneuploidies by massively parallel sequencing of maternal plasma DNA has been considered as a screening method in clinical practices ([@b14-etm-0-0-4272]). Up to now, several studies have been carried out to focus on the application of such a technique on the screening for the T13, T18 and T21 ([@b14-etm-0-0-4272]--[@b16-etm-0-0-4272]). For example, Liang and collegues reported the efficiency of NIPT based on 412 samples with full karyotyping and sequencing results ([@b11-etm-0-0-4272]). These authors showed a detection sensitivity of 100% and a specificity of 99.71%, and indicated that the NIPT of fetal chromosome aneuploidies for all 24 chromosomes was feasible in a single sequencing event. In our study, a large sample size with a total of 1,901 cases was used. On this basis, we evaluated the efficiency and clinical performance of NIPT in the screening for the T13, T18 and T21, respectively. We found that, among the 22 NIPT-positive pregnant women, all chose to be informed of the potential results, suggesting that most of the pregnant women want to know the potential information as much as possible in order to make the final decision. Most of the patients (86.3%) decided to undergo amniotic fluid puncture. For the cases (n=1483) with negative NIPT findings, 1,418 (95.61%) were normal at birth, indicating the efficiency of NIPT screening was extremely feasible as previously described in other studies.

Serum screening technique has been commonly used in the clinical practice in the past decades. Giving an estimated detection sensitivity of 90% and a rate of false positivity of 2--5%; the most commonly used method for the screening of Down syndrome and T18 being based on the combination of maternal age, ultrasound examination findings of the fetus, as well as the concentration of related markers ([@b17-etm-0-0-4272],[@b18-etm-0-0-4272]). Such a method is labor-consuming and involves extensive procedures. Invasive methods with amniocentesis as a representative method, is effective for the prescreening with definite results, but such a technique bears a miscarriage rate of 0.5% ([@b10-etm-0-0-4272]). Compared with these methods, the NIPT technique is non-invasive (with only a blood sample collection of \<10 ml) and easy to perform. In 2012, the committee of Prenatal Diagnosis in China gave positive opinion on the NIPT technique ([@b19-etm-0-0-4272]). On this basis, it is reasonable to believe that the application of NIPT in clinical practice may be further extended.

Indeed, the NIPT is suitable to the screening of pregnant women at a gestational age of 12+0 to 26+6 weeks, which is more extensive than the serum screening (12+0 to 16+6 weeks) and amniotic fluid puncture (16+0 to 22+6 weeks), respectively ([@b3-etm-0-0-4272]). Another advantage of the NIPT is the satisfactory sensitivity and specificity ([@b20-etm-0-0-4272]). In our study, the sensitivity of the prior screening test for T21 was 88.89%, but the specificity was only 29.13% while the NIPT showed 100% for both sensitivity and specificity for T21 screening. For the T18, the sensitivity and specificity was, respectively, 73.27 and 98.20% for the conventional screening test relatively to 100 and 99.86% for NIPT. Compared with the conventional methods, the sensitivity and specificity of NIPT for the screening of T18 and T21 was remarkably higher. However, the sensitivity of detection of T13 was 99.93%, but the specificity was not satisfactory, suggesting that large samples are still needed to focus on the performance of NIPT for the screening of T13.

In conclusion, NIPT technique is feasible for the prenatal screening of T18 and T21 with higher sensitivity and specificity compared with conventional methods. We believe that the genome sequencing-based NIPT technique is applicable in clinical practice, and deserves extensive application in future.

###### 

Basic characteristics of the 1,901 pregnant women of NIPT.

  Characteristics                                                           No. (%)
  ------------------------------------------------------------------------- ---------------------
  Maternal age (years)                                                      
    ≤20                                                                     0.21% (4/1,901)
    20--24                                                                  8.63% (164/1,901)
    25--29                                                                  40.50% (770/1,901)
    30--34                                                                  25.25% (480/1,901)
    35--39                                                                  21.25% (404/1,901)
    40--44                                                                  4.00% (76/1,901)
    ≥45                                                                     0.16% (3/1,901)
    Mean                                                                    30.57
    Range                                                                   19--45
  Gestation at NIPT test (weeks)                                            
    12+0 to 12+6                                                            1.00% (19/1,901)
    13+0 to 13+6                                                            1.63% (31/1,901)
    14+0 to 14+6                                                            1.68% (32/1,901)
    15+0 to 15+6                                                            3.26% (62/1,901)
    16+0 to 16+6                                                            7.26% (138/1,901)
    17+0 to 17+6                                                            17.31% (329/1,901)
    18+0 to 18+6                                                            21.25% (404/1,901)
    19+0 to 19+6                                                            16.10% (306/1,901)
    20+0 to 20+6                                                            10.89% (207/1,901)
    21+0 to 21+6                                                            8.15% (155/1,901)
    22+0 to 22+6                                                            4.73% (90/1,901)
    23+0 to 23+6                                                            3.16% (60/1,901)
    24+0 to 24+6                                                            1.53% (29/1,901)
    25+0 to 25+6                                                            0.68% (13/1,901)
    26+0 to 26+6                                                            0.58% (11/1,901)
    27+0 to 27+6                                                            0.11% (2/1,901)
    28+0 to 28+6                                                            0.16% (3/1,901)
    29+0 to 29+6                                                            0.00% (0/1,901)
    30+0 to 30+6                                                            0.11% (2/1,901)
    31+0 to 31+6                                                            0.11% (2/1,901)
    32+0 to 32+6                                                            0.05% (1/1,901)
    Unknown                                                                 0.26% (5/1,901)
  Ultrasound findings                                                       
    Normal                                                                  91.16% (1733/1,901)
    Unknown                                                                 1.63% (31/1,901)
  Abnormal ultrasonographic soft markers or ultrasound anomalies            7.15% (136/1,901)
    Thickened NT/NF                                                         0.16% (3/1,901)
    Echogenic heart focus                                                   4.21% (80/1,901)
    Renal pelvic dilatation                                                 0.11% (2/1,901)
    Echogenic heart focus + renal pelvic dilatation                         0.16% (3/1,901)
    Echogenic heart focus + renal pelvic dilatation+ choroid plexus cysts   0.05% (1/1,901)
    Renal pelvic dilatation + widened ventricle                             0.05% (1/1,901)
    Echogenic heart focus + choroid plexus cysts                            0.16% (3/1,901)
    Choroid plexus cysts                                                    0.42% (8/1,901)
    Widened ventricle                                                       0.26% (5/1,901)
    Echogenic heart focus + widened ventricle                               0.21% (4/1,901)
    Echogenic heart focus + widened ventricle +small nasal bone             0.05% (1/1,901)
    Echogenic heart focus + widened ventricle + thickened NF                0.05% (1/1,901)
    Echogenic bowel                                                         0.16% (3/1,901)
    Echogenic heart focus + echogenic bowel                                 0.05% (1/1,901)
    Absent nasal bone                                                       0.05% (1/1,901)
    Echogenic heart focus + small nasal bone                                0.05% (1/1,901)
    Tricuspid regurgitation                                                 0.05% (1/1,901)
    Others                                                                  0.89% (17/1,901)
  Prior screening test                                                      
    High risk (T21)                                                         49.55% (942/1,901)
    Critical high risk (T21)                                                14.94% (284/1,901)
    High risk (T18)                                                         1.16% (22/1,901)
    Critical high risk (T18)                                                0.16% (3/1,901)
    High risk (T21+T18)                                                     0.11% (2/1,901)
    Critical high risk (T21+T18)                                            0.11% (2/1,901)
    Low risk                                                                3.58% (68/1,901)
    None                                                                    28.83% (548/1,901)
    Unknown                                                                 1.58% (30/1,901)
  Previous trisomy 21 pregnancies                                           0.32% (6/1,901)
    Pregnancy by assisted reproductive techniques                           1.53% (29/1,901)

NIPT, non-invasive prenatal testing.

###### 

Details of the 22 non-invasive prenatal testing (NIPT) positive cases.

                                                                           NIPT                                      
  ----- --------------- ---- ----------------------- -------------- ------ ------ ---------------------------------- --------------------------
    1   13B0148333      31   Normal                    1:45 (T21)   21+5   T21    47,XN,+21                          Termination of pregnancy
    2   13B0148379R     37   Normal                  --             22+5   T18    46,XN                              Normal
    3   14B1017282      38   Normal                  Unknown        19     T21    47,XN,+21                          Termination of pregnancy
    4   14B1017311      32   Normal                  Unknown        14+5   T21    47,XN,+21                          Termination of pregnancy
    5   14B1017323      24   Normal                    1:26 (T21)   17+2   T21    47,XN,+21                          Termination of pregnancy
    6   15B1103208D     29   A vanishing twin        --             16+2   T18                                       Stillbirth
    7   PDB12AC00025    37   Normal                    1:33 (T21)   17+2   T21    47,XN,+21                          Termination of pregnancy
    8   PDB12AC00114    34   Normal                    1:55 (T21)   18+4   T21    --                                 Intrauterine fetal death
    9   PDB12AC00146    27   Echogenic heart focus     1:25 (T21)   20+2   T21    47,XN,+21                          Termination of pregnancy
  10    PDB13AC00011    31   Normal                  1:166 (T21)    18+2   T21    47,XN,+21                          Termination of pregnancy
  11    PDB13AC00027R   33   Normal                  1:144 (T21)    21     T13    Declined                           Termination of pregnancy
  12    PDB13AC00166    30   Normal                  1:140 (T21)    18+3   T21    47,XN,+21                          Termination of pregnancy
  13    PDB13AC00213R   33   Normal                  1:100 (T21)    22     T18    Declined                           Termination of pregnancy
  14    PDB13AC00484R   28   Normal                    1:20 (T21)   18+2   T21    --                                 Intrauterine fetal death
  15    PDB13AC00485    33   Normal                    1:37 (T21)   16+5   T21    Declined                           Loss to follow up
  16    PDB13AC00614    29   Echogenic heart focus   1:280 (T21)    21+5   T21    47,XN,+21                          Termination of pregnancy
  17    PDB13AC00729    31   Norma                   1:270 (T21)    18+6   T21    47,XN,+21                          Termination of pregnancy
  18    PDB13AC00834    30   Normal                  1:260 (T21)    15+5   T13    46,XN                              Normal
  19    PDB13AC00952    40   Normal                  --             12+5   T21    47,XN,+21                          Termination of pregnancy
  20    PDB13AC01023    24   Normal                  1:270 (T21)    19+5   T18    47,XY, +18(70%) 48,XYY, +18(30%)   Termination of pregnancy
  21    PDB13AC01225    22   Normal                  1:177 (T21)    19+2   T21    47,XN,+21                          Termination of pregnancy
  22    PDB13AC01245R   27   Normal                  1:270 (T21)    21     T18    46,XN                              Normal

###### 

The pregnancy outcome of 1,879 NIPT negative cases.

  Follow-up                                                    No. of the cases (%)
  ------------------------------------------------------------ ----------------------
  Fetal outcome available                                      1,483 (78.92)
    Confirmed normal at birth                                  1,418 (75.47)
    Still birth                                                  59 (3.14)
    Neonatal death                                               1 (0.05)
    Termination of pregnancy                                     5 (0.27)
      Abnormal ultrasound findings                               2 (0.11)
      Abnormal ultrasound findings-chromosomal abnormalities     1 (0.05)
      Personal reason                                            2 (0.11)
  Loss to follow-up                                              396 (21.08)
    Failed to contact                                            390 (20.76)
    Refused to provide information                               6 (0.32)

NIPT, non-invasive prenatal testing.

###### 

Comparison of specificity (Sp) and sensitivity (Se) of NIPT and prior screening test.

  A, T21                                                                                                                      
  -------------------- ---------------------- -------- -------- -------- -------- ---------- ------ -------- ------- -------- -----------------------------------------------------------------------------
  High risk              752                  88.89%   29.08%   70.92%   1.06%    10         100%   100%     0%      100%     8(47,XN,+21); 2(Intrauterine fetal death)
  Critical high risk     234                  88.89%   29.08%   70.92%   1.06%    1          100%   100%     0%      100%     1(47,XN,+21)
  Low risk               72                   88.89%   29.08%   70.92%   1.06%    0          100%   100%     0%      100%     --
  None                   377                  --       --       --       --       1          100%   100%     0%      100%     1(47,XN,+21)
  Unknown                9                    --       --       --       --       2          100%   100%     0%      100%     2(47,XN,+21)
  Total                1,444                  --       --       --       --       14         100%   100%     0%      100%     12(47,XN,+21); 2(Intrauterine fetal death)
                                                                                                                              
  B, T18                                                                                                                      
                                                                                                                              
                       Prior screening test   NIPT                                                                            
                                                                                                                              
  Results              No.                    Se       Sp       FPV      PPV      Positive   Se     Sp       FPV     PPV      Validation
                                                                                                                              
  High risk              19                   0%       98.20%   1.80%    0/0+10   0          100%   99.86%   0.14%   33.33%   --
  Critical high risk     4                    0%       98.20%   1.80%    0/0+10   0          100%   99.86%   0.14%   33.33%   --
  Low risk             1,035                  0%       98.20%   1.80%    0/0+10   3          100%   99.86%   0.14%   33.33%   1\[47,XY,+18(70%); 48,XYY,+18(30%)\]; 1(Termination of pregnancy); 1(46,XN)
  None                   377                  --       --       --       --       1          100%   99.86%   0.14%   33.33%   1(46,XN)
  Unknown                9                    --       --       --       --       0          100%   99.86%   0.14%   33.33%   --
  Total                1,444                  --       --       --       --       4          100%   99.86%   0.14%   33.33%   1\[47,XY,+18(70%); 48,XYY,+18(30%)\]; 1(Terminationof pregnancy); 2(46,XN)
                                                                                                                              
  C, T13                                                                                                                      
                                                                                                                              
                       Prior screening test   NIPT                                                                            
                                                                                                                              
  Results              No.                    Se       Sp       FPV      PPV      Positive   Se     Sp       FPV     PPV      Validation
                                                                                                                              
  Total                --                     --       --       --       --       2          0%     99.93%   0.07%   0%       1(Termination of pregnancy); 1(46, XN)

NIPT, non-invasive prenatal testing.
